Therapeutic Areas | Psychiatry
Psychiatry | Latuda® (lurasidone HCI)
Psychiatry | Resources
Psychiatry | Disease State
Psychiatry | Disease State | Bipolar Depression
Psychiatry | Disease State | Schizophrenia
Psychiatry | Disease State | General Psychiatry
Psychiatry | Latuda® (lurasidone HCI) | Publications
Therapeutic Areas | Neurology
Neurology | Aptiom® (eslicarbazepine acetate)
Neurology | Kynmobi® (apomorphine hydrochloride)
Neurology | Resources
Neurology | Disease State
Neurology | Disease State | Parkinson's
Neurology | Disease State | Epilepsy
Neurology | Disease State | General Neurology
| Publications
| Publications
Therapeutic Areas | Respiratory
Respiratory | Brovana® (arformoterol tartrate)
Respiratory | Lonhala® Magnair® (glycopyrrolate)
Respiratory | Xopenex HFA® (levalbuterol tartrate)
Respiratory | Resources
Respiratory | Disease State
Respiratory | Disease State | COPD
Respiratory | Disease State | General Respiratory
| Publications
| Publications
| Publications
Submit Medical Inquiry
Engage With Field Medical
Resources
Adverse Event & Product Complaint Reporting
Pipeline
| SEP-363856
| SEP-363856 | Schizophrenia 4 Weeks
| SEP-363856 | Schizophrenia 26 Weeks
| SEP-363856 | PD Psychosis 6 Weeks
| SEP-4199
| SEP-4199 | 6 Week
Search Medical Information
Scientific Conferences
Search Medical Information
Therapeutic Button
Psychiatry
Neurology
Respiratory
Submit Medical Inquiry Button Field Medical Button Resources Button AEPC Button Pipeline Button
Home
Therapeutic Area
Psychiatry
Neurology
Respiratory
submit medical inquiry
Engage With Field Medical
resources
adverse event & product complaint reporting
pipeline
back
Pipeline
click to view
Ulotaront (SEP-363856)
Schizophrenia
Ulotaront (SEP-363856)
Adjunctive major depressive disorder
Ulotaront (SEP-363856)
Generalized anxiety disorder
click to view
SEP-4199
Bipolar depression
click to view
Ulotaront (SEP-363856)
Parkinson's disease psychosis
DSP-3905
Neuropathic pain
SEP-378614
Treatment-resistant depression
SEP-380135
Agitation in Alzheimer's disease
DSP-0038
Alzheimer's disease psychosis
DSP-3456
Treatment-resistant depression
DSP-2342
To be determined
These are investigational compounds whose safety and efficacy have not been reviewed or approved by the FDA
change slide left button
Image for Pshychiatry therapeutic area Conferences
change slide left button
SUNOVION and are registered trademarks of Sumitomo Pharma Co., Ltd.
Sunovion Pharmaceuticals Inc. is a U.S. subsidiary of Sumitomo Pharma Co., Ltd.
APTIOM is a registered trademark of , used under license.
LATUDA is a registered trademark of Sumitomo Pharma Co., Ltd.
© 2023 Sunovion Pharmaceuticals Inc. All rights reserved.
Terms of Use | Privacy Notice and Cookie Notice | Contact Us

Please rate your experience on Sunovionmedical.com: